Phase II study of etoposide for carcinoma of the prostate.

Journal Article (Clinical Trial;Journal Article)

The treatment of prostate carcinoma with the epipodophyllotoxin derivative etoposide was studied in a multi-institutional phase II trial. An iv dose schedule of 130 mg/m2 daily for 3 days every 3 weeks was utilized. A total of 36 patients were evaluable; the observed total response was 3%. Moderate toxicity (predominantly myelosuppression) was seen utilizing this treatment schedule. It is concluded that etoposide possesses little single-agent therapeutic activity for prostate carcinoma.

Full Text

Duke Authors

Cited Authors

  • Walther, PJ; Williams, SD; Troner, M; Greco, FA; Birch, R; Einhorn, LH

Published Date

  • June 1986

Published In

Volume / Issue

  • 70 / 6

Start / End Page

  • 771 - 772

PubMed ID

  • 3524825

International Standard Serial Number (ISSN)

  • 0361-5960


  • eng

Conference Location

  • United States